tirzepatide on shortage list FDA Announced Removal of from the Drug Mounjaro will remain off shortage

Conclusion The GLP-1 drug market is rapidly expanding, driving strong enthusiasm among companies for the development of GLP-1 medications

And that's why for me it is - "It depends" answer

A patient losing 1520% of body weight often experiences 1020% reductions in triglycerides and measurable improvements in HDL cholesterol, the protective form

Zepbound (Tirzepatide) Touted for its superior weight loss outcomes, Zepbound addresses both GLP-1 and GIP receptors, achieving up to 20.9% weight loss in clinical trials

This medication is intended for long-term use as part of a comprehensive weight management program.

By October 1, 2024, there were 1,090 cases pending in MDL 3092, which includes Novo Nordisk, the company that makes Wegovy